16 results on '"GeurtsvanKessel, C.H."'
Search Results
2. Antibody and T-Cell Responses 6 Months after Coronavirus Disease 2019 Messenger RNA-1273 Vaccination in Patients with Chronic Kidney Disease, on Dialysis, or Living with a Kidney Transplant
- Author
-
Sanders, J.F., Messchendorp, A.L., Vries, R.D. de, Baan, C.C., Baarle, D. van, Binnendijk, R. van, Diavatopoulos, D.A., Geers, D., Schmitz, K.S., GeurtsvanKessel, C.H., Hartog, G. den, Kho, M.M., Koopmans, M.P., Molen, R.G. van der, Remmerswaal, E.B.M., Rots, N., Gansevoort, R.T., Bemelman, F.J., Hilbrands, L.B., Reinders, M.E., Virology, Internal Medicine, Experimental Immunology, AII - Inflammatory diseases, AII - Infectious diseases, and Nephrology
- Subjects
Microbiology (medical) ,Infectious Diseases ,All institutes and research themes of the Radboud University Medical Center ,SDG 3 - Good Health and Well-being ,lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4] ,COVID-19 ,dialysis ,kidney transplantation ,Renal disorders Radboud Institute for Health Sciences [Radboudumc 11] ,Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5] ,chronic kidney disease ,mRNA-1273 vaccine - Abstract
Background The immune response to COVID-19 vaccination is inferior in kidney transplant recipients (KTRs) and to a lesser extent in patients on dialysis or with chronic kidney disease (CKD). We assessed the immune response 6 months after mRNA-1273 vaccination in kidney patients and compared this to controls. Methods A total of 152 participants with CKD stages G4/5 (eGFR Results At 6 months after vaccination, S1-specific antibodies were detected in 100% of controls, 98.7% of CKD G4/5 patients, 95.1% of dialysis patients, and 56.6% of KTRs. These figures were comparable to the response rates at 28 days, but antibody levels waned significantly. Neutralization of the ancestral and Delta variants was detected in most participants, whereas neutralization of Omicron was mostly absent. S-specific T-cell responses were detected at 6 months in 75.0% of controls, 69.4% of CKD G4/5 patients, 52.6% of dialysis patients, and 12.9% of KTRs. T-cell responses at 6 months were significantly lower than responses at 28 days. Conclusions Although seropositivity rates at 6 months were comparable to rates at 28 days after vaccination, significantly decreased antibody levels and T-cell responses were observed. The combination of low antibody levels, reduced T-cell responses, and absent neutralization of the newly emerging variants indicates the need for additional boosts or alternative vaccination strategies in KTRs. Clinical Trials Registration NCT04741386.
- Published
- 2023
3. Timing and sequence of vaccination against COVID-19 and influenza (TACTIC): a single-blind, placebo-controlled randomized clinical trial.
- Author
-
Dulfer, E.A., Geckin, B., Taks, E.J.M., GeurtsvanKessel, C.H., Dijkstra, H.I., Emst, J.E. van, Gaast-de Jongh, C.E. van der, Mourik, D. van, Koopmans, P.C., Dominguez Andres, J., Crevel, R. van, Maat, J.S. van de, Jonge, M.I. de, Netea, M.G., Dulfer, E.A., Geckin, B., Taks, E.J.M., GeurtsvanKessel, C.H., Dijkstra, H.I., Emst, J.E. van, Gaast-de Jongh, C.E. van der, Mourik, D. van, Koopmans, P.C., Dominguez Andres, J., Crevel, R. van, Maat, J.S. van de, Jonge, M.I. de, and Netea, M.G.
- Abstract
01 juni 2023, Item does not contain fulltext, BACKGROUND: Novel mRNA-based vaccines have been used to protect against SARS-CoV-2, especially in vulnerable populations who also receive an annual influenza vaccination. The TACTIC study investigated potential immune interference between the mRNA COVID-19 booster vaccine and the quadrivalent influenza vaccine, and determined if concurrent administration would have effects on safety or immunogenicity. METHODS: TACTIC was a single-blind, placebo-controlled randomized clinical trial conducted at the Radboud University Medical Centre, the Netherlands. Individuals ≥60 years, fully vaccinated against COVID-19 were eligible for participation and randomized into one of four study groups: 1) 0.5 ml influenza vaccination Vaxigrip Tetra followed by 0.3 ml BNT162b2 COVID-19 booster vaccination 21 days later, (2) COVID-19 booster vaccination followed by influenza vaccination, (3) influenza vaccination concurrent with the COVID-19 booster vaccination, and (4) COVID-19 booster vaccination only (reference group). Primary outcome was the geometric mean concentration (GMC) of IgG against the spike (S)-protein of the SARS-CoV-2 virus, 21 days after booster vaccination. We performed a non-inferiority analysis of concurrent administration compared to booster vaccines alone with a predefined non-inferiority margin of -0.3 on the log10-scale. FINDINGS: 154 individuals participated from October, 4, 2021, until November, 5, 2021. Anti-S IgG GMCs for the co-administration and reference group were 1684 BAU/ml and 2435 BAU/ml, respectively. Concurrent vaccination did not meet the criteria for non-inferiority (estimate -0.1791, 95% CI -0.3680 to -0.009831) and antibodies showed significantly lower neutralization capacity compared to the reference group. Reported side-effects were mild and did not differ between study groups. INTERPRETATION: Concurrent administration of both vaccines is safe, but the quantitative and functional antibody responses were marginally lower compared to booster vaccin
- Published
- 2023
4. Timing and sequence of vaccination against COVID-19 and influenza - Author's reply.
- Author
-
Dulfer, E.A., Geckin, B., Taks, E.J.M., GeurtsvanKessel, C.H., Dijkstra, H.I., Emst, J.E. van, Gaast-de Jongh, C.E. van der, Koopmans, P.C., Dominguez Andres, J., Crevel, R. van, Maat, J.S. van de, Jonge, M.I. de, Netea, M.G., Dulfer, E.A., Geckin, B., Taks, E.J.M., GeurtsvanKessel, C.H., Dijkstra, H.I., Emst, J.E. van, Gaast-de Jongh, C.E. van der, Koopmans, P.C., Dominguez Andres, J., Crevel, R. van, Maat, J.S. van de, Jonge, M.I. de, and Netea, M.G.
- Abstract
01 juli 2023, Item does not contain fulltext
- Published
- 2023
5. The role of interleukin-21 in COVID-19 vaccine-induced B cell-mediated immune responses in patients with kidney disease and kidney transplant recipients.
- Author
-
Malahe, S.R.K., Hartog, Y.D., Rietdijk, W.J.R., Baarle, D. van, Kuiper, R. de, Reijerkerk, D., Ras, A.M., Geers, D., Diavatopoulos, D.A., Messchendorp, A.L., Molen, R.G. van der, Remmerswaal, E.B.M., Bemelman, F.J., Gansevoort, R.T., Hilbrands, L.B., Sanders, J.S., GeurtsvanKessel, C.H., Kho, M.M.L., Vries, R.D. de, Reinders, M.E.J., Baan, C.C., Malahe, S.R.K., Hartog, Y.D., Rietdijk, W.J.R., Baarle, D. van, Kuiper, R. de, Reijerkerk, D., Ras, A.M., Geers, D., Diavatopoulos, D.A., Messchendorp, A.L., Molen, R.G. van der, Remmerswaal, E.B.M., Bemelman, F.J., Gansevoort, R.T., Hilbrands, L.B., Sanders, J.S., GeurtsvanKessel, C.H., Kho, M.M.L., Vries, R.D. de, Reinders, M.E.J., and Baan, C.C.
- Abstract
01 september 2023, Contains fulltext : 296138.pdf (Publisher’s version ) (Open Access), T-cell-mediated help to B cells is required for the development of humoral responses, in which the cytokine interleukin (IL)-21 is key. Here, we studied the mRNA-1273 vaccine-induced SARS-CoV-2-specific memory T-cell IL-21 response, memory B cell response, and immunoglobulin (Ig)G antibody levels in peripheral blood at 28 days after the second vaccination by ELISpot and the fluorescent bead-based multiplex immunoassay, respectively. We included 40 patients with chronic kidney disease (CKD), 34 patients on dialysis, 63 kidney transplant recipients (KTR), and 47 controls. We found that KTR, but not patients with CKD and those receiving dialysis, showed a significantly lower number of SARS-CoV-2-specific IL-21 producing T cells than controls (P < .001). KTR and patients with CKD showed lower numbers of SARS-CoV-2-specific IgG-producing memory B cells when compared with controls (P < .001 and P = .01, respectively). The T-cell IL-21 response was positively associated with the SARS-CoV-2-specific B cell response and the SARS-CoV-2 spike S1-specific IgG antibody levels (both Pearson r = 0.5; P < .001). In addition, SARS-CoV-2-specific B cell responses were shown to be IL-21 dependent. Taken together, we show that IL-21 signaling is important in eliciting robust B cell-mediated immune responses in patients with kidney disease and KTR.
- Published
- 2023
6. Immune Responses 6 Months After mRNA-1273 COVID-19 Vaccination and the Effect of a Third Vaccination in Patients with Inborn Errors of Immunity.
- Author
-
Leeuwen, L.P.M. van, Grobben, M., GeurtsvanKessel, C.H., Ellerbroek, P.M., Bree, G.J. de, Potjewijd, J., Rutgers, A., Jolink, H., Veerdonk, F.L. van de, Gils, M.J. van, Vries, R.D. de, Dalm, V.A.S.H., Leeuwen, L.P.M. van, Grobben, M., GeurtsvanKessel, C.H., Ellerbroek, P.M., Bree, G.J. de, Potjewijd, J., Rutgers, A., Jolink, H., Veerdonk, F.L. van de, Gils, M.J. van, Vries, R.D. de, and Dalm, V.A.S.H.
- Abstract
01 augustus 2023, Contains fulltext : 294958.pdf (Publisher’s version ) (Open Access), PURPOSE: Patients with inborn errors of immunity (IEI) are at increased risk of severe coronavirus disease-2019 (COVID-19). Effective long-term protection against COVID-19 is therefore of great importance in these patients, but little is known about the decay of the immune response after primary vaccination. We studied the immune responses 6 months after two mRNA-1273 COVID-19 vaccines in 473 IEI patients and subsequently the response to a third mRNA COVID-19 vaccine in 50 patients with common variable immunodeficiency (CVID). METHODS: In a prospective multicenter study, 473 IEI patients (including X-linked agammaglobulinemia (XLA) (N = 18), combined immunodeficiency (CID) (N = 22), CVID (N = 203), isolated or undefined antibody deficiencies (N = 204), and phagocyte defects (N = 16)), and 179 controls were included and followed up to 6 months after two doses of the mRNA-1273 COVID-19 vaccine. Additionally, samples were collected from 50 CVID patients who received a third vaccine 6 months after primary vaccination through the national vaccination program. SARS-CoV-2-specific IgG titers, neutralizing antibodies, and T cell responses were assessed. RESULTS: At 6 months after vaccination, the geometric mean antibody titers (GMT) declined in both IEI patients and healthy controls, when compared to GMT 28 days after vaccination. The trajectory of this decline did not differ between controls and most IEI cohorts; however, antibody titers in CID, CVID, and isolated antibody deficiency patients more often dropped to below the responder cut-off compared to controls. Specific T cell responses were still detectable in 77% of controls and 68% of IEI patients at 6 months post vaccination. A third mRNA vaccine resulted in an antibody response in only two out of 30 CVID patients that did not seroconvert after two mRNA vaccines. CONCLUSION: A similar decline in IgG titers and T cell responses was observed in patients with IEI when compared to healthy controls 6 months after mRNA-127
- Published
- 2023
7. Factors associated with long-term antibody response after COVID-19 vaccination in patients treated with systemic treatment for solid tumors
- Author
-
Oosting, S.F., Veldt, A.A.M. van der, Fehrmann, R.S.N., Bhattacharya, A., Binnendijk, R.S. van, GeurtsvanKessel, C.H., Dingemans, A.C., Smit, E.F., Hiltermann, T.J.N., Hartog, G. den, Jalving, M., Westphal, T.T., Wilt, F. de, Ernst, S.M., Boerma, A., Zijl, L. van, Rimmelzwaan, G.F., Kvistborg, P., Els, C.A.C.M. van, Rots, N.Y., Baarle, D. van, Haanen, J.B.A.G., Vries, E.G.E. de, Oosting, S.F., Veldt, A.A.M. van der, Fehrmann, R.S.N., Bhattacharya, A., Binnendijk, R.S. van, GeurtsvanKessel, C.H., Dingemans, A.C., Smit, E.F., Hiltermann, T.J.N., Hartog, G. den, Jalving, M., Westphal, T.T., Wilt, F. de, Ernst, S.M., Boerma, A., Zijl, L. van, Rimmelzwaan, G.F., Kvistborg, P., Els, C.A.C.M. van, Rots, N.Y., Baarle, D. van, Haanen, J.B.A.G., and Vries, E.G.E. de
- Abstract
Item does not contain fulltext
- Published
- 2023
8. Seroprevalence of SARS-CoV-2 antibodies among healthcare workers in Dutch hospitals after the 2020 first wave: a multicentre cross-sectional study with prospective follow-up.
- Author
-
Recanatini, C., GeurtsvanKessel, C.H., Pas, S.D., Broens, E.M., Maas, M, Mansfeld, R. van, Mutsaers-van Oudheusden, A.J.G., Rijen, M. van, Schippers, E.F., Stegeman, A., Tami, A., Veldkamp, K.E., Visser, H., Voss, A., Wegdam-Blans, M.C., Wertheim, H.F.L., Wever, P.C., Koopmans, M.P., Kluytmans, Jan, Kluytmans-van den Bergh, M.F.Q., Recanatini, C., GeurtsvanKessel, C.H., Pas, S.D., Broens, E.M., Maas, M, Mansfeld, R. van, Mutsaers-van Oudheusden, A.J.G., Rijen, M. van, Schippers, E.F., Stegeman, A., Tami, A., Veldkamp, K.E., Visser, H., Voss, A., Wegdam-Blans, M.C., Wertheim, H.F.L., Wever, P.C., Koopmans, M.P., Kluytmans, Jan, and Kluytmans-van den Bergh, M.F.Q.
- Abstract
Item does not contain fulltext, BACKGROUND: We aimed to estimate the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence and describe its determinants and associated symptoms among unvaccinated healthcare workers (HCWs) after the first wave of the pandemic. METHODS: HCWs from 13 Dutch hospitals were screened for antibodies against the spike protein of SARS-CoV-2 in June-July 2020 and after three months. Participants completed a retrospective questionnaire on determinants for occupational and community exposure to SARS-CoV-2 and symptoms suggestive of COVID-19 experienced since January 2020. The seroprevalence was calculated per baseline characteristic and symptom at baseline and after follow-up. Adjusted odds ratios (aOR) for seropositivity were determined using logistic regression. RESULTS: Among 2328 HCWs, 323 (13.9%) were seropositive at enrolment, 49 of whom (15%) reported no previous symptoms suggestive of COVID-19. During follow-up, only 1% of the tested participants seroconverted. Seroprevalence was higher in younger HCWs compared to the mid-age category (aOR 1.53, 95% CI 1.07-2.18). Nurses (aOR 2.21, 95% CI 1.34-3.64) and administrative staff (aOR 1.87, 95% CI 1.02-3.43) had a higher seroprevalence than physicians. The highest seroprevalence was observed in HCWs in the emergency department (ED) (aOR 1.79, 95% CI 1.10-2.91), the lowest in HCWs in the intensive, high, or medium care units (aOR 0.47, 95% CI 0.31-0.71). Chronic respiratory disease, smoking, and having a dog were independently associated with a lower seroprevalence, while HCWs with diabetes mellitus had a higher seroprevalence. In a multivariable model containing all self-reported symptoms since January 2020, altered smell and taste, fever, general malaise/fatigue, and muscle aches were positively associated with developing antibodies, while sore throat and chills were negatively associated. CONCLUSIONS: The SARS-CoV-2 seroprevalence in unvaccinated HCWs of 13 Dutch hospitals was 14% in June-July 2020 an
- Published
- 2023
9. One-year data on immunogenicity and breakthrough infections in patients with solid tumors vaccinated against COVID-19 during systemic cancer treatment
- Author
-
van der Veldt, A.A.M., primary, Oosting, S.F., additional, Fehrmann, R.S.N., additional, GeurtsvanKessel, C.H., additional, van Binnendijk, R.S., additional, Dingemans, A.-M.C., additional, Smit, E.F., additional, Hiltermann, T.J.N., additional, den Hartog, G., additional, Jalving, M., additional, Westphal, T.T., additional, Bhattacharya, A., additional, de Wilt, F., additional, Ernst, Sophie M., additional, Boerma, A., additional, van Zijl, L., additional, Rimmelzwaan, G.F., additional, Kvistborg, P., additional, van Els, C.A.C.M., additional, Rots, N.Y., additional, van Baarle, D., additional, Haanen, J.B.A.G., additional, and de Vries, E.G.E., additional
- Published
- 2023
- Full Text
- View/download PDF
10. Analyzing the immunogenicity of bivalent booster vaccinations in healthcare workers: The SWITCH ON trial protocol
- Author
-
Tan, N.H., Sablerolles, R.S.G., Rietdijk, W.J.R., Goorhuis, A., Postma, D.F., Visser, L.G., Bogers, S., Geers, D., Zaeck, L.M., Koopmans, M.P.G., Dalm, V.A.S.H., Kootstra, N.A., Huckriede, A.L.W., Baarle, D. van, Lafeber, M., GeurtsvanKessel, C.H., Vries, R.D. de, Kuy, P.H.M. van der, Pharmacy, Virology, Immunology, Internal Medicine, Infectious diseases, AII - Infectious diseases, APH - Aging & Later Life, APH - Global Health, Experimental Immunology, Translational Immunology Groningen (TRIGR), and Microbes in Health and Disease (MHD)
- Subjects
mRNA vaccine ,SDG 3 - Good Health and Well-being ,Immunology ,Immunology and Allergy ,COVID-19 ,adenovirus-based vaccine ,immune memory ,immune response - Abstract
Vaccination against coronavirus disease 2019 (COVID-19) has contributed greatly to providing protection against severe disease, thereby reducing hospital admissions and deaths. Several studies have reported reduction in vaccine effectiveness over time against the Omicron sub-lineages. However, the willingness to receive regular booster doses in the general population is declining. To determine the need for repeated booster vaccinations in healthy individuals and to aid policymakers in future public health interventions for COVID-19, we aim to gain insight into the immunogenicity of the additional bivalent booster vaccination in a representative sample of the healthy Dutch population. The SWITCH ON study was initiated to investigate three main topics: i) immunogenicity of bivalent vaccines after priming with adenovirus- or mRNA-based vaccines, ii) immunological recall responses and reactivity with relevant variants after booster vaccination, and iii) the necessity of booster vaccinations for the healthy population in the future.Clinical trial registrationhttps://clinicaltrials.gov/, identifier NCT05471440.
- Published
- 2022
11. Durability of immune responses after boosting in Ad26.COV2.S-primed healthcare workers
- Author
-
Sablerolles, R.S.G., Rietdijk, W.J.R., Goorhuis, A., Postma, D.F., Visser, L.G., Schmitz, K.S., Geers, D., Bogers, S., Haren, E. van, Koopmans, M.P.G., Dalm, V.A.S.H., Kootstra, N.A., Huckriede, A.L.W., Akkerman, R., Beukema, M., Lafeber, M., Baarle, D. van, Vries, R.D. de, Kuy, P.H.M. van der, GeurtsvanKessel, C.H., SWITCH Res Grp, Translational Immunology Groningen (TRIGR), Microbes in Health and Disease (MHD), Pharmaceutical Technology and Biopharmacy, Pharmacy, Internal Medicine, Virology, Immunology, Infectious diseases, AII - Infectious diseases, APH - Aging & Later Life, APH - Global Health, and Experimental Immunology
- Subjects
Microbiology (medical) ,COV2 ,Ad26 ,Infectious Diseases ,Ad26.COV2.S ,SDG 3 - Good Health and Well-being ,SARS-CoV-2 ,waning immunity - Abstract
The emergence of SARS-CoV-2 variants raised questions regarding the durability of immune responses after homologous or heterologous boosters after Ad26.COV2.S-priming. We found that SARS-CoV-2–specific binding antibodies, neutralizing antibodies, and T cells are detectable 5 months after boosting, although waning of antibodies and limited cross-reactivity with Omicron BA.1 was observed.
- Published
- 2022
12. Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming
- Author
-
Sablerolles, R.S.G., Rietdijk, W.J.R., Goorhuis, A., Postma, D.F., Visser, L.G., Geers, D., Schmitz, K.S., Garrido, H.M.G., Koopmans, M.P.G., Dalm, V.A.S.H., Kootstra, N.A., Huckriede, A.L.W., Lafeber, M., Baarle, D. van, GeurtsvanKessel, C.H., Vries, R.D. de, Kuy, P.H.M. van der, SWITCH Res Grp, Pharmacy, Virology, Immunology, Internal Medicine, Translational Immunology Groningen (TRIGR), Microbes in Health and Disease (MHD), Infectious diseases, AII - Infectious diseases, APH - Aging & Later Life, APH - Global Health, Graduate School, and Experimental Immunology
- Subjects
Adult ,Male ,COVID-19 Vaccines ,Ad26COVS1 ,SARS-CoV-2 ,T-Lymphocytes ,Immunization, Secondary ,General Medicine ,Middle Aged ,Antibodies, Viral ,Antibodies, Neutralizing ,complex mixtures ,Interferon-gamma ,Immunogenicity, Vaccine ,SDG 3 - Good Health and Well-being ,Immunoglobulin G ,Humans ,Female ,Single-Blind Method ,Original Article ,BNT162 Vaccine ,2019-nCoV Vaccine mRNA-1273 - Abstract
BACKGROUND: The Ad26.COV2.S vaccine, which was approved as a single-shot immunization regimen, has been shown to be effective against severe coronavirus disease 2019. However, this vaccine induces lower severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S)-specific antibody levels than those induced by messenger RNA (mRNA)-based vaccines. The immunogenicity and reactogenicity of a homologous or heterologous booster in persons who have received an Ad26.COV2.S priming dose are unclear.METHODS: In this single-blind, multicenter, randomized, controlled trial involving health care workers who had received a priming dose of Ad26.COV2.S vaccine, we assessed immunogenicity and reactogenicity 28 days after a homologous or heterologous booster vaccination. The participants were assigned to receive no booster, an Ad26.COV2.S booster, an mRNA-1273 booster, or a BNT162b2 booster. The primary end point was the level of S-specific binding antibodies, and the secondary end points were the levels of neutralizing antibodies, S-specific T-cell responses, and reactogenicity. A post hoc analysis was performed to compare mRNA-1273 boosting with BNT162b2 boosting.RESULTS: Homologous or heterologous booster vaccination in 434 participants resulted in higher levels of S-specific binding antibodies, neutralizing antibodies, and T-cell responses than a single Ad26.COV2.S vaccination. The increase in binding antibodies was significantly larger with heterologous regimens that included mRNA-based vaccines than with the homologous booster. The mRNA-1273 booster was most immunogenic and was associated with higher reactogenicity than the BNT162b2 and Ad26.COV2.S boosters. Local and systemic reactions were generally mild to moderate in the first 2 days after booster administration.CONCLUSIONS: The Ad26.COV2.S and mRNA boosters had an acceptable safety profile and were immunogenic in health care workers who had received a priming dose of Ad26.COV2.S vaccine. The strongest responses occurred after boosting with mRNA-based vaccines. Boosting with any available vaccine was better than not boosting. (Funded by the Netherlands Organization for Health Research and Development ZonMw; SWITCH ClinicalTrials.gov number, NCT04927936.).
- Published
- 2022
13. Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity
- Author
-
Leeuwen, L.P.M. van, GeurtsvanKessel, C.H., Ellerbroek, P.M., Bree, G.J. de, Potjewijd, J., Rutgers, A., Jolink, H., Veerdonk, F.L. van de, Gorp, E.C. van, Wilt, F. de, Bogers, S., Gommers, L., Geers, D., Bruns, A.H., Leavis, H.L., Haga, J.W. van, Lemkes, B.A., Veen, A. van der, Kruijf-Bazen, S.F.J. de, Paassen, P. van, Leeuw, K. de, Ven, A van der, Verbeek-Menken, P.H., Wengen, A. van, Arend, S.M., Ruten-Budde, A.J., Ent, M.W. van der, Hagen, P.M. van, Sanders, R.W., Grobben, M., Straten, K. van der, Burger, Jacobus W.A., Poniman, M., Nierkens, S., Gils, M.J. van, Vries, R.D. de, Dalm, V., Leeuwen, L.P.M. van, GeurtsvanKessel, C.H., Ellerbroek, P.M., Bree, G.J. de, Potjewijd, J., Rutgers, A., Jolink, H., Veerdonk, F.L. van de, Gorp, E.C. van, Wilt, F. de, Bogers, S., Gommers, L., Geers, D., Bruns, A.H., Leavis, H.L., Haga, J.W. van, Lemkes, B.A., Veen, A. van der, Kruijf-Bazen, S.F.J. de, Paassen, P. van, Leeuw, K. de, Ven, A van der, Verbeek-Menken, P.H., Wengen, A. van, Arend, S.M., Ruten-Budde, A.J., Ent, M.W. van der, Hagen, P.M. van, Sanders, R.W., Grobben, M., Straten, K. van der, Burger, Jacobus W.A., Poniman, M., Nierkens, S., Gils, M.J. van, Vries, R.D. de, and Dalm, V.
- Abstract
Item does not contain fulltext, BACKGROUND: Patients with inborn errors of immunity (IEI) are at increased risk of severe coronavirus disease-2019 (COVID-19). Effective vaccination against COVID-19 is therefore of great importance in this group, but little is known about the immunogenicity of COVID-19 vaccines in these patients. OBJECTIVES: We sought to study humoral and cellular immune responses after mRNA-1273 COVID-19 vaccination in adult patients with IEI. METHODS: In a prospective, controlled, multicenter study, 505 patients with IEI (common variable immunodeficiency [CVID], isolated or undefined antibody deficiencies, X-linked agammaglobulinemia, combined B- and T-cell immunodeficiency, phagocyte defects) and 192 controls were included. All participants received 2 doses of the mRNA-1273 COVID-19 vaccine. Levels of severe acute respiratory syndrome coronavirus-2-specific binding antibodies, neutralizing antibodies, and T-cell responses were assessed at baseline, 28 days after first vaccination, and 28 days after second vaccination. RESULTS: Seroconversion rates in patients with clinically mild antibody deficiencies and phagocyte defects were similar to those in healthy controls, but seroconversion rates in patients with more severe IEI, such as CVID and combined B- and T-cell immunodeficiency, were lower. Binding antibody titers correlated well to the presence of neutralizing antibodies. T-cell responses were comparable to those in controls in all IEI cohorts, with the exception of patients with CVID. The presence of noninfectious complications and the use of immunosuppressive drugs in patients with CVID were negatively correlated with the antibody response. CONCLUSIONS: COVID-19 vaccination with mRNA-1273 was immunogenic in mild antibody deficiencies and phagocyte defects and in most patients with combined B- and T-cell immunodeficiency and CVID. Lowest response was detected in patients with X-linked agammaglobulinemia and in patients with CVID with noninfectious complications. The assessmen
- Published
- 2022
14. LBA8 Vaccination against SARS-CoV-2 in patients receiving chemotherapy, immunotherapy, or chemo-immunotherapy for solid tumors
- Author
-
Oosting, S., primary, Van der Veldt, A.A.M., additional, GeurtsvanKessel, C.H., additional, Fehrmann, R.S.N., additional, van Binnendijk, R.S., additional, Dingemans, A-M.C., additional, Smit, E.F.F., additional, Hiltermann, T.J.N., additional, den Hartog, G., additional, Jalving, M., additional, Westphal, T., additional, Battacharya, A., additional, van der Heiden, M., additional, Blank, C.U., additional, Koopmans, M.P., additional, van Els, C.A., additional, Rots, N.Y., additional, van Baarle, D., additional, Haanen, J.B.A.G., additional, and de Vries, E.G., additional
- Published
- 2021
- Full Text
- View/download PDF
15. Genomic sequence of yellow fever virus from a Dutch traveller returning from the Gambia-Senegal region, the Netherlands, November 2018
- Author
-
Phan, M.V.T., Darwish Murad, S. (Sarwa), Eijck, A.A. (Annemiek), Metselaar, H.J. (Herold), Hartog, H. (Hermien), Harinck, F. (Femme), GeurtsvanKessel, C.H., Molenkamp, R. (Richard), Cotten, M. (Matthew), Koopmans D.V.M., M.P.G. (Marion), Phan, M.V.T., Darwish Murad, S. (Sarwa), Eijck, A.A. (Annemiek), Metselaar, H.J. (Herold), Hartog, H. (Hermien), Harinck, F. (Femme), GeurtsvanKessel, C.H., Molenkamp, R. (Richard), Cotten, M. (Matthew), and Koopmans D.V.M., M.P.G. (Marion)
- Published
- 2019
- Full Text
- View/download PDF
16. Yellow fever in a traveller returning from Suriname to the Netherlands, March 2017
- Author
-
Wouthuyzen-Bakker, M., Knoester, M., Berg, A.P. van den, GeurtsvanKessel, C.H., Koopmans, M.P., Leer-Buter, C. Van, Velthuis, B., Pas, S.D., Ruijs, W.L.M., Schmidt-Chanasit, J., Vreden, S.G., Werf, T.S. van der, Reusken, C.B., Bierman, W.F., Wouthuyzen-Bakker, M., Knoester, M., Berg, A.P. van den, GeurtsvanKessel, C.H., Koopmans, M.P., Leer-Buter, C. Van, Velthuis, B., Pas, S.D., Ruijs, W.L.M., Schmidt-Chanasit, J., Vreden, S.G., Werf, T.S. van der, Reusken, C.B., and Bierman, W.F.
- Abstract
Item does not contain fulltext, A Dutch traveller returning from Suriname in early March 2017, presented with fever and severe acute liver injury. Yellow fever was diagnosed by (q)RT-PCR and sequencing. During hospital stay, the patient's condition deteriorated and she developed hepatic encephalopathy requiring transfer to the intensive care. Although yellow fever has not been reported in the last four decades in Suriname, vaccination is recommended by the World Health Organization for visitors to this country.
- Published
- 2017
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.